Net income was RMB98.7 million ($15.5 million) in the first nine months 2011, up 13.1% from RMB87.2 million in the first nine months 2010.
Basic and diluted earnings per ADS for the first nine months 2011 were RMB2.08 ($0.33), up 16.2% from basic and diluted earnings per ADS of RMB1.79 in the first nine months 2010.
Adjusted EBITDA (non-GAAP)(C) was RMB243.9 million ($38.2) million for the first nine months 2011, up 12.8% from RMB216.3 million for the same period 2010.
In the first nine months 2011, capital expenditures were RMB212.6 million ($33.3 million), depreciation expense was RMB69.2 million ($10.7 million), and amortization of acquired intangibles was RMB19.1 million ($3.0 million).
Revenue Outlook Maintained for 2011Based on current market and operating conditions, planned business expansion, and estimated patient volume, Concord Medical is maintaining its prior revenue outlook for the year 2011, as shown below.
The Company expects to generate net revenues in an estimated range of RMB480 million to RMB520 million for the year 2011, which would be an increase of approximately 23% to 33% in net revenues from 2010. This estimated range includes revenues from the Chang'an CMS International Cancer Center ("CCICC") preliminary operations but excludes any potential future revenue from the Chang'an Hospital, as the acquisition of Chang'an Hospital's equity interests is currently pending. The Company notes that any unanticipated delays in completing the acquisition of Chang'an Hospital, any failure to obtain CCICC's clinical license, and other uncertainties may result in CCICC not achieving its expected contribution to the Company, which in turn
|SOURCE Concord Medical Services Holdings Limited|
Copyright©2010 PR Newswire.
All rights reserved